MALVERN, Pa.--(BUSINESS WIRE)--Human Genome Sciences (HGS: NASDAQ: HGSI) announced that BENLYSTA TM met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with ...
This morning, Citigroup (C) lowered its price target on shares of Human Genome Sciences (HGSI) to $15 as sales of Benlysta have been lighter than originally expected. In the report, Citigroup reduced ...
Green Dot (GDOT) was downgraded today by Morgan Stanley (MS) to equal weight from overweight with a price target of $25 due to competitive and regulatory pressures currently facing the company. Shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback